X-RAY imaging

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis2
62Paroxysmal nocturnal hemoglobinuria1
65Primary immunodeficiency1
IDDisease name (Link within this page)Number of trials
284Diamond-Blackfan anemia1
286Hereditary sideroblastic anemia1

28. Systemic amyloidosis


Clinical trials : 335Drugs : 274 - (DrugBank : 86) / Drug target genes : 47 - Drug target pathways : 165 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

62. Paroxysmal nocturnal hemoglobinuria


Clinical trials : 358Drugs : 160 - (DrugBank : 35) / Drug target genes : 33 - Drug target pathways : 116 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

65. Primary immunodeficiency


Clinical trials : 798Drugs : 585 - (DrugBank : 118) / Drug target genes : 100 - Drug target pathways : 216 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

284. Diamond-Blackfan anemia


Clinical trials : 39Drugs : 95 - (DrugBank : 35) / Drug target genes : 34 - Drug target pathways : 131 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

286. Hereditary sideroblastic anemia


Clinical trials : 7Drugs : 25 - (DrugBank : 10) / Drug target genes : 19 - Drug target pathways : 64 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries